The role of complement in Alzheimer's disease pathology

被引:81
作者
Emmerling, MR [1 ]
Watson, MD [1 ]
Raby, CA [1 ]
Spiegel, K [1 ]
机构
[1] Warner Lambert Parke Davis, Parke Davis Pharmaceut Res Div, Neurosci Therapeut, Ann Arbor, MI 48106 USA
来源
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE | 2000年 / 1502卷 / 01期
关键词
beta-amyloid peptide; inflammation; neurodegeneration; microglia;
D O I
10.1016/S0925-4439(00)00042-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Complement proteins are integral components of amyloid plaques and cerebral vascular amyloid ill Alzheimer brains. They can be found at the earliest stages of amyloid deposition and their activation coincides with the clinical expression of Alzheimer's dementia. This review will examine the origins of complement in the brain and the role of P-amyloid peptide (AP) in complement activation in Alzheimer's disease, an event that might serve as a nidus of chronic inflammation. Pharmacology therapies that may serve to inhibit A beta-mediated complement activation will also be discussed. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:158 / 171
页数:14
相关论文
共 169 条
  • [1] A randomized controlled trial of prednisone in Alzheimer's disease
    Aisen, PS
    Davis, KL
    Berg, JD
    Schafer, K
    Campbell, K
    Thomas, RG
    Weiner, MF
    Farlow, MR
    Sano, M
    Grundman, M
    Thal, LJ
    [J]. NEUROLOGY, 2000, 54 (03) : 588 - 593
  • [2] A pilot study of prednisone in Alzheimer's disease
    Aisen, PS
    Marin, D
    Altstiel, L
    Goodwin, C
    Baruch, B
    Jacobson, R
    Ryan, T
    Davis, KL
    [J]. DEMENTIA, 1996, 7 (04): : 201 - 206
  • [3] ALBUMIN AND IMMUNOGLOBULIN IN PLASMA AND CEREBROSPINAL-FLUID, AND BLOOD-CEREBROSPINAL FLUID BARRIER FUNCTION IN PATIENTS WITH DEMENTIA OF ALZHEIMER TYPE AND MULTI-INFARCT DEMENTIA
    ALAFUZOFF, I
    ADOLFSSON, R
    BUCHT, G
    WINBLAD, B
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 1983, 60 (03) : 465 - 472
  • [4] PHARMACOLOGICAL STUDIES OF FUT-175, NAFAMSTAT MESILATE .1. INHIBITION OF PROTEASE ACTIVITY IN INVITRO AND INVIVO EXPERIMENTS
    AOYAMA, T
    INO, Y
    OZEKI, M
    ODA, M
    SATO, T
    KOSHIYAMA, Y
    SUZUKI, S
    FUJITA, M
    [J]. JAPANESE JOURNAL OF PHARMACOLOGY, 1984, 35 (03) : 203 - 227
  • [5] PRODUCTION AND INTERFERON-GAMMA-MEDIATED REGULATION OF COMPLEMENT COMPONENT C2 AND FACTOR-B AND FACTOR-D BY THE ASTROGLIOMA CELL-LINE U105-MG
    BARNUM, SR
    ISHII, Y
    AGRAWAL, A
    VOLANAKIS, JE
    [J]. BIOCHEMICAL JOURNAL, 1992, 287 : 595 - 601
  • [6] INTERFERON-GAMMA REGULATION OF C3-GENE EXPRESSION IN HUMAN ASTROGLIOMA CELLS
    BARNUM, SR
    JONES, JL
    BENVENISTE, EN
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 1992, 38 (03) : 275 - 282
  • [7] COMPLEMENT BIOSYNTHESIS IN THE CENTRAL-NERVOUS-SYSTEM
    BARNUM, SR
    [J]. CRITICAL REVIEWS IN ORAL BIOLOGY AND MEDICINE, 1995, 6 (02) : 132 - 146
  • [8] BARNUM SR, 1999, KEYSTONE S EFFECTORS, P47
  • [9] Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins
    Borchelt, DR
    Ratovitski, T
    vanLare, J
    Lee, MK
    Gonzales, V
    Jenkins, NA
    Copeland, NG
    Price, DL
    Sisodia, SS
    [J]. NEURON, 1997, 19 (04) : 939 - 945
  • [10] Familial Alzheimer's disease-linked presenilin 1 variants elevate A beta 1-42/1-40 ratio in vitro and in vivo
    Borchelt, DR
    Thinakaran, G
    Eckman, CB
    Lee, MK
    Davenport, F
    Ratovitsky, T
    Prada, CM
    Kim, G
    Seekins, S
    Yager, D
    Slunt, HH
    Wang, R
    Seeger, M
    Levey, AI
    Gandy, SE
    Copeland, NG
    Jenkins, NA
    Price, DL
    Younkin, SG
    [J]. NEURON, 1996, 17 (05) : 1005 - 1013